Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer

British Journal of Cancer

Volumn 94, Issue 7, 2006, Pages 1035-1040

  Kubben, F J G M ^a   Sier, C F M ^a   Van Duijn, W ^a   Griffioen, G ^a   Hanemaaijer, R ^b   Van De Velde, C J H ^a   Van Krieken, J H J M ^c   Lamers, C B H W ^a   Verspaget, H W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Gelatinases; MMP 7; MMP 8; MMP 9; TIMP; Tissue inhibitor of metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; BIOASSAY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN VARIANT; STOMACH CANCER; STOMACH MUCOSA; TISSUE SECTION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 33645739961     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603041     Document Type: Article

References (26)

1. Ajisaka H, Yonemura Y, Miwa K (2004) Correlation of lymph node metastases and expression of matrix metalloproteinase-7 in patients with gastric cancer. Hepatogastroenterology 51: 900-905
2. Allgayer H, Babic R, Beyer BC, Grutzner KU, Tarabichi A, Schildberg FW, Heiss MM (1998) Prognostic relevance of MMP-2 (72-kDa collagenase IV) in gastric cancer. Oncology 55: 152-160
3. Bergmann U, Michaelis J, Oberhoff R, Knauper V, Beckmann R, Tschesche H (1989) Enzyme linked immunosorbent assays (ELISA) for the quantitative determination of human leukocyte collagenase and gelatinase. J Clin Chem Clin Biochem 27: 351-359
4. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW (2002) Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86: 1864-1870
5. Chuanzhong Y, Ming G, Fanglin Z, Haijiao C, Zhen L, Shiping C, YongKang Z (2002) Real-time quantitative reverse transcription - PCR assay for renal cell carcinoma-associated antigen G250. Clin Chim Acta 318: 33-40
6. Elnemr A, Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, Tochiori S, Endou Y, Sasaki T (2003) Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer. Gastric Cancer 6: 30-38
7. Hanemaaijer R, Verheijen JH, Maguire TM, Visser H, Toet K, McDermott E, O'Higgins N, Duffy MJ (2000) Increased gelatinase-A and gelatinase-B activities in malignant vs benign breast tumors. Int J Cancer 86: 204-207
8. Hanemaaijer R, Visser H, Konttinen YT, Koolwijk P, Verheijen JH (1998) A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels. Matrix Biol 17: 657-665
9. Hermanek P, Sobin LH (1992) UICC TNM classification of malignant tumors, 4th edn. London: Springer
10. Itoh Y, Takamura A, Ito N, Maru Y, Sato H, Suenaga N, Aoki T, Seiki M (2001) Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J 20: 4782-4793
11. Ji F, Chen YL, Jin EY, Wang WL, Yang ZL, Li YM (2005) Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer. World J Gastroenterol 11: 3222-3226
12. Joo YE, Seo KS, Kim HS, Rew JS, Park CS, Kim SJ (2000) Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig Dis Sci 45: 114-121
13. Kabashima A, Maehara Y, Kakeji Y, Baba H, Koga T, Sugimachi K (2000) Clinicopathological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res 6: 3581-3584
14. Kabashima A, Yao T, Sugimachi K, Tsuneyoshi M (2002) Relationship between biologic behavior and phenotypic expression in intramucosal gastric carcinomas. Hum Pathol 33: 80-86
15. Koyama S (2004) Enhanced cell surface expression of matrix metalloproteinases and their inhibitors, and tumor-induced host response in progression of human gastric carcinoma. Dig Dis Sci 49: 1621-1630
16. Liu LX, Liu ZH, Jiang HC, Qu X, Zhang WH, Wu LF, Zhu AL, Wang XQ, Wu M (2002a) Profiling of differentially expressed genes in human gastric carcinoma by cDNA expression array. World J Gastroenterol 8: 580-585
17. Liu XP, Kawauchi S, Oga A, Tsushimi K, Tsushimi M, Furuya T, Sasaki K (2002b) Prognostic significance of matrix metalloproteinase-7 (MMP-7) expression at the invasive front in gastric carcinoma. Jpn J Cancer Res 93: 291-295
18. McCawley LJ, Matrisian LM (2001) Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol 13: 534-540
19. Mönig SP, Baldus SE, Hennecken JK, Spiecker DB, Grass G, Schneider PM, Thiele J, Dienes HP, Holscher AH (2001) Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 39: 597-602
20. Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P (2004) Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 49: 179-186
21. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB, Verspaget HW (1996) Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74: 413-417
22. Torii A, Kodera Y, Ito M, Shimizu Y, Hirai T, Yasui K, Morimoto T, Yamamura Y, Kato T, Hayakawa T, Fujimoto N, Kito T (1998) Matrix metalloproteinase 9 in mucosally invasive gastric cancer. Gastric Cancer 1: 142-145
23. Yokoyama T, Nakamura H, Otani Y, Kubota T, Fujimoto N, Seiki M, Kitajima M, Okada Y (2004) Differences between scirrhous and non-scirrhous human gastric carcinomas from the aspect of proMMP-2 activation regulated by TIMP-3. Clin Exp Metast 21: 223-233
24. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, Noguchi Y (2001) Intratumoral concentrations of tissue inhibitor of matrix metalloproteinase 1 in patients with gastric carcinoma: a new biomarker for invasion and its impact on survival. Cancer 91: 1739-1744
25. Zhang S, Li L, Lin JY, Lin H (2003) Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol 9: 899-904
26. Zucker S, Cao J, Chen WT (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19: 6642-6650